首页/数据集/Table S7 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

Table S7 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

NIAID Data Ecosystem2026-04-29 收录

肿瘤靶向治疗

MAPK通路抑制剂

数据链接：

https://figshare.com/articles/dataset/Table_S7_from_LXH254_a_Potent_and_Selective_ARAF-Sparing_Inhibitor_of_BRAF_and_CRAF_for_the_Treatment_of_MAPK-Driven_Tumors/22480653 数据链接链接失效反馈

官方服务：

资源简介：

In vivo anti-tumor effects of LXH254 and Trametinib

应用场景：

创建时间：

2021-04-01

肿瘤靶向治疗

药物耐药机制

Protein arginine methyltransferase 5 (PRMT5) over-expression in hematological and solid tumors methylates arginine residues on cellular proteins involved in important cancer functions including cell c

NIAID Data Ecosystem90

Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

EGFR突变肺癌耐药机制

肿瘤靶向治疗

Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

Figshare2022-11-02 更新30

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

肿瘤靶向治疗

ErbB抑制剂临床研究

This is a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that have select mutations or alterations in human epidermal growth factor receptor 2 (HE

NIAID Data Ecosystem20

肿瘤靶分子临床研究信息数据集

肿瘤靶向治疗

临床研究

聚焦肿瘤靶分子临床研究全流程，整合靶点发现、临床试验设计、疗效数据、安全性评估等核心信息。数据经标准化清洗与专业校验，关联靶点分子结构、作用机制及临床结果，支持科研机构靶点验证、药企药物研发、临床机构方案优化，为靶分子临床转化提供高质量、可溯源的数据支撑。

江苏数据交易所80

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

肿瘤靶向治疗

肿瘤免疫调节

Purinostat Mesylate (PM), a highly selective HDAC I/IIb inhibitor, exhibits excellent antitumor activity in multiple MM and lymphoma cell lines and multiple mouse models, outperforming the pan-HDAC in

NIAID Data Ecosystem20

Table S7 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

资源简介：

相关数据集